(KVUE) Kenvue - Overview
Stock: Medications, Skincare, Haircare, Oral Care, Baby Products
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.07% |
| Yield on Cost 5y | 3.39% |
| Yield CAGR 5y | 43.70% |
| Payout Consistency | 100.0% |
| Payout Ratio | 100.7% |
| Risk 5d forecast | |
|---|---|
| Volatility | 26.5% |
| Relative Tail Risk | -11.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.47 |
| Alpha | -21.84 |
| Character TTM | |
|---|---|
| Beta | 0.226 |
| Beta Downside | 0.253 |
| Drawdowns 3y | |
|---|---|
| Max DD | 44.08% |
| CAGR/Max DD | -0.26 |
Description: KVUE Kenvue January 28, 2026
Kenvue Inc. (NYSE:KVUE) is a global consumer-health company operating in North America, Europe, the Middle East, Africa, Asia-Pacific and Latin America. It is organized into three product lines: Self-Care (e.g., Tylenol, Motrin, Benadryl, Nicorette), Skin Health & Beauty (e.g., Neutrogena, Aveeno, Rogaine) and Essential Health (e.g., Listerine, Johnson’s, Band-Aid). The firm was spun out of Johnson & Johnson in 2022 and is headquartered in Summit, New Jersey.
In its most recent fiscal quarter (Q4 2025), Kenvue reported net sales of $5.2 billion, a 4.1 % year-over-year increase, driven primarily by a 6.3 % rise in Self-Care volume and modest price-inflation offsets in the Skin Health & Beauty segment. Adjusted earnings per share were $1.12, up from $0.97 a year earlier, while operating margin expanded to 14.5 % after cost-saving initiatives reduced SG&A expense by $120 million.
Key macro drivers for the personal-care sector include: (1) an aging global population that lifts demand for OTC pain-relief and wound-care products; (2) sustained consumer preference for “clean” and dermatologist-endorsed skin-care brands, which is expanding the premium-price segment; and (3) inflation-linked input-cost volatility (e.g., raw-material price indices up ~3 % YoY) that pressures pricing power, making efficiency gains a critical competitive lever.
For a deeper, data-driven view of KVUE’s valuation dynamics, you may find it worthwhile to explore the analytics platform ValueRay.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 1.43b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.81 > 1.0 |
| NWC/Revenue: -0.83% < 20% (prev -0.03%; Δ -0.79% < -1%) |
| CFO/TA 0.08 > 3% & CFO 2.14b > Net Income 1.43b |
| Net Debt (7.97b) to EBITDA (2.94b): 2.71 < 3 |
| Current Ratio: 0.98 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.92b) vs 12m ago -0.05% < -2% |
| Gross Margin: 58.14% > 18% (prev 0.58%; Δ 5757 % > 0.5%) |
| Asset Turnover: 55.40% > 50% (prev 57.42%; Δ -2.01% > 0%) |
| Interest Coverage Ratio: 5.22 > 6 (EBITDA TTM 2.94b / Interest Expense TTM 455.0m) |
Altman Z'' 0.21
| A: -0.00 (Total Current Assets 6.03b - Total Current Liabilities 6.16b) / Total Assets 27.25b |
| B: -0.00 (Retained Earnings -136.0m / Total Assets 27.25b) |
| C: 0.09 (EBIT TTM 2.37b / Avg Total Assets 27.09b) |
| D: -0.32 (Book Value of Equity -5.25b / Total Liabilities 16.61b) |
| Altman-Z'' Score: 0.21 = B |
Beneish M -3.19
| DSRI: 0.87 (Receivables 2.42b/2.85b, Revenue 15.01b/15.46b) |
| GMI: 0.99 (GM 58.14% / 57.78%) |
| AQI: 0.98 (AQ_t 0.70 / AQ_t-1 0.71) |
| SGI: 0.97 (Revenue 15.01b / 15.46b) |
| TATA: -0.03 (NI 1.43b - CFO 2.14b) / TA 27.25b) |
| Beneish M-Score: -3.19 (Cap -4..+1) = AA |
What is the price of KVUE shares?
Over the past week, the price has changed by -2.25%, over one month by +0.40%, over three months by +23.73% and over the past year by -16.57%.
Is KVUE a buy, sell or hold?
- StrongBuy: 3
- Buy: 2
- Hold: 14
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the KVUE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 19.3 | 11.1% |
| Analysts Target Price | 19.3 | 11.1% |
| ValueRay Target Price | 19.5 | 12.3% |
KVUE Fundamental Data Overview January 29, 2026
P/E Forward = 16.0256
P/S = 2.2343
P/B = 3.1782
P/EG = 0.9009
Revenue TTM = 15.01b USD
EBIT TTM = 2.37b USD
EBITDA TTM = 2.94b USD
Long Term Debt = 7.06b USD (from longTermDebt, last quarter)
Short Term Debt = 1.95b USD (from shortTermDebt, last quarter)
Debt = 9.11b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.97b USD (from netDebt column, last quarter)
Enterprise Value = 41.50b USD (33.53b + Debt 9.11b - CCE 1.14b)
Interest Coverage Ratio = 5.22 (Ebit TTM 2.37b / Interest Expense TTM 455.0m)
EV/FCF = 25.32x (Enterprise Value 41.50b / FCF TTM 1.64b)
FCF Yield = 3.95% (FCF TTM 1.64b / Enterprise Value 41.50b)
FCF Margin = 10.92% (FCF TTM 1.64b / Revenue TTM 15.01b)
Net Margin = 9.55% (Net Income TTM 1.43b / Revenue TTM 15.01b)
Gross Margin = 58.14% ((Revenue TTM 15.01b - Cost of Revenue TTM 6.28b) / Revenue TTM)
Gross Margin QoQ = 59.14% (prev 58.90%)
Tobins Q-Ratio = 1.52 (Enterprise Value 41.50b / Total Assets 27.25b)
Interest Expense / Debt = 1.02% (Interest Expense 93.0m / Debt 9.11b)
Taxrate = 24.33% (128.0m / 526.0m)
NOPAT = 1.80b (EBIT 2.37b * (1 - 24.33%))
Current Ratio = 0.98 (Total Current Assets 6.03b / Total Current Liabilities 6.16b)
Debt / Equity = 0.86 (Debt 9.11b / totalStockholderEquity, last quarter 10.63b)
Debt / EBITDA = 2.71 (Net Debt 7.97b / EBITDA 2.94b)
Debt / FCF = 4.86 (Net Debt 7.97b / FCF TTM 1.64b)
Total Stockholder Equity = 10.27b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.29% (Net Income 1.43b / Total Assets 27.25b)
RoE = 13.95% (Net Income TTM 1.43b / Total Stockholder Equity 10.27b)
RoCE = 13.69% (EBIT 2.37b / Capital Employed (Equity 10.27b + L.T.Debt 7.06b))
RoIC = 9.48% (NOPAT 1.80b / Invested Capital 18.95b)
WACC = 5.47% (E(33.53b)/V(42.64b) * Re(6.75%) + D(9.11b)/V(42.64b) * Rd(1.02%) * (1-Tc(0.24)))
Discount Rate = 6.75% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 0.21%
[DCF Debug] Terminal Value 84.36% ; FCFF base≈1.54b ; Y1≈1.29b ; Y5≈959.7m
Fair Price DCF = 11.13 (EV 29.30b - Net Debt 7.97b = Equity 21.33b / Shares 1.92b; r=5.90% [WACC]; 5y FCF grow -19.65% → 2.90% )
EPS Correlation: -44.40 | EPS CAGR: -1.54% | SUE: -0.34 | # QB: 0
Revenue Correlation: 18.55 | Revenue CAGR: 0.22% | SUE: -0.75 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.26 | Chg30d=-0.001 | Revisions Net=-1 | Analysts=6
EPS next Year (2026-12-31): EPS=1.10 | Chg30d=-0.004 | Revisions Net=-2 | Growth EPS=+6.9% | Growth Revenue=+2.6%